Recent data from a major international trial reveals a striking finding: postmenopausal patients with intermediate-risk breast cancer achieve nearly identical five-year survival rates whether treated with chemotherapy plus hormone therapy (93.9%) or hormone therapy alone (93.8%).
This negligible 0.1% survival difference, derived from the RxPONDER trial of over 5,000 patients, challenges current treatment paradigms and highlights the power of genetic testing in personalized oncology. The Oncotype DX test identifies which patients benefit from chemotherapy and which can avoid its significant side effects without compromising outcomes.
The implications are substantial: clinicians can now use genetic risk stratification to make evidence-based decisions that reduce patient burden while maintaining therapeutic efficacy. For postmenopausal women in particular, hormone therapy alone emerges as an equivalent treatment option when supported by genetic testing data, offering a less toxic alternative that preserves quality of life.
Read the full article on GMJ Newsroom.
Was this article helpful?
